A recent focus in clinical immunodiagnostics is to improve sensitivity of assays for rare circulating protein biomarkers. The ability to detect low concentrations of certain biomarkers translates to diagnosis of disease at an earlier stage, which can positively impact prognosis and disease management (1) (2) (3) . In research (for example in the discovery and development of new biomarkers), targeted assays for individual proteins are often required before multiplexing strategies are developed. Cross-reactivity of antibodies often compromises assay sensitivity in multiplexed immunoassays (4 ) . Ultrasensitive individual assays consume only small sample volumes, a characteristic that can be advantageous in the case of scarce archival clinical samples.
The development of single-molecule detection approaches has provided new opportunities for improving immunoassay sensitivity and miniaturization (5 ) . Fluorescence confocal microscopy with laser-induced excitation enables single-molecule detection in extremely small interrogation zones (on the order of femtoliters). By reducing interrogation zones to these dimensions and carefully tuning the timescales of the data acquisition and molecular flow rates, background interference is decreased and individual molecules are readily recorded as discrete fluorescence bursts above background (6 ) . Counting these bursts, or molecular events, by applying fluorescence thresholds on the basis of the internally derived background noise generates experimental data whose precision is dictated by counting statistics. Hence, sample read times can be adjusted to achieve a desired counting precision. The combination of small interrogation volumes and short sample read times can also lead to rapid analysis.
Despite the advantages of single-molecule detection and the development of single-molecule detection instruments, adaptation of this technology to quantification of serum or plasma analytes has only scarcely been reported in the literature [for example, (7 ) ]. Building on our previous work (8 ), we constructed single-molecule immunoassays (SMIAs) that use immune capture of analytes on microparticles, tagging with biotinylated antibodies, and quantification of fluorophore-labeled streptavidin molecules recovered from the microparticles by use of singlemolecule fluorescence spectroscopy. Measurements were performed on the Trilogy ® 2020 Single Molecule Analyzer (U.S. Genomics), an instrument capable of detecting photon bursts corresponding to individual fluorescent molecules (see Fig. S1A inset in the Data Supplement that accompanies the online version of this Abstract of Oak Ridge Poster at http://www.clinchem.org/content/ vol53/issue11). The analytical sensitivity for detection of Alexa 647-labeled streptavidin (SA-A647, Molecular Probes), labeled with approximately 3 dye molecules, in 36 s was measured to be Ͻ3 fmol/L (see Fig. S1A in online Data Supplement), similar to what we previously reported for detection of antibodies labeled with comparable numbers of dye molecules under similar conditions (8 ) . In principle, therefore, SMIAs could detect antigen at 60 pg/L (assuming an analyte molecular weight of 20 kDa) and even further with sample enrichment, signal amplification, or longer read times. The signal response increased linearly up to approximately 100 pmol/L of SA-A647, demonstrating linearity in the signal response over the approximate 10 5 -fold range of reporter molecule concentrations.
We constructed SMIA capture reagents by activating approximately 5-m diameter polystyrene beads (Bangs) with N-hydroxysulfosuccinimide and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (Pierce) and by reacting the activated beads with monoclonal antibodies (R&D Systems) to covalently affix the antibodies. Biotinylated monoclonal or polyclonal antibodies (R&D Systems) known to serve as matched pairs to the capture antibodies were selected as detection reagents. Proteins for use as calibrators were purchased from R&D Systems. Immune complexes were formed in MultiScreen HTS, BV microfiltration plates (Millipore) in 3 successive steps (capture of analyte to microparticles, binding of captured antigen with biotinylated detection antibodies, and binding of SA-A647 to bound detection antibodies) separated by removal of unbound material with microfiltration on a MultiScreen HTS vacuum manifold (Millipore) and extensive washing. Finally, bound reporter molecules were released from the capture beads by application of a low pH elution buffer and separated from the beads by microfiltration. After neutralization, the microtiter plate was placed into the Trilogy 2020, and eluate was drawn from each well and passed directly through the singlemolecule analyzer in an automated fashion.
Calibration curves from SMIAs for tumor necrosis factor (TNF) (Table 1) . These assay limits are comparable, if not superior, to those published for ELISA and cytometric bead immunoassays (see Table S1 in the online Data Supplement). Furthermore, the LODs lie at or below the middle of the typical physiological range, 0 -10 ng/L (TNF-␣), 0.1-32 ng/L (IFN-␥), and Ͻ10 -503 ng/L (MCP-1) (see Table S1 in the online Data Supplement), suggesting suitability of the assays for clinical research. Within-day Abstracts of Oak Ridge Posters imprecision in calibrator signals was low (see Table S2 in the online Data Supplement): mean (low to high) intraassay CVs of signals for all calibrators were 8.5% (3.3%-23%; TNF-␣), 11% (5.2%-19%; IFN-␥), and 9.7% (5.4%-23%; MCP-1). Between-day imprecision in calibrator signals was equally low: mean (low to high) interassay CVs of signals for all calibrators were 5.7% (2.4%-11%; TNF-␣), 13% (3.5%-32%; IFN-␥), and 10% (5.3%-14%; MCP-1). Within-and between-day CVs of calibrator concentrations back-calculated with the fitted calibration curves were also good, averaging 9.5% and 5.7% (TNF-␣), 19% and 9% (IFN-␥), and 9.6% and 12% (MCP-1), respectively, for all calibrators above LODs. The limits of quantification (LOQs) were estimated as the lowest concentrations of calibrator yielding CVs Ͻ20%. In all cases, LOQs were in the low nanogram per liter range: Ͻ1.3 ng/L (TNF-␣), Ͻ1.4 ng/L (IFN-␥), and Ͻ2.7 ng/L (MCP-1). Together, these data show that SMIAs can be sensitive and precise.
Calibration curves were used to quantify analytes in small volumes (5 L) of defibrinated human plasma (BBI Diagnostics) containing calibrators added at low, medium, and high concentrations of 20, 200 , and 2000 ng/L, which correspond to 1.25, 12.5, and 125 ng/L upon dilution in the SMIA. Recoveries of the added analytes were generally good, ranging from 91%-96% (TNF-␣), 72%-95% (IFN-␥), and 39%-93% (MCP-1) ( Table 1 ). The relatively poor recovery (39%) of 20-ng added MCP-1/L reflects the challenge of measuring a 20% increase in a Quantification from human plasma, alone or with the indicated concentrations of pure material added. Concentrations expressed for undiluted plasma. Within-day CV calculated as the mean of intraassay CVs (SD ϫ 100%/mean) for observed concentrations. Between-day CV calculated as the interassay CVs for observed concentrations. Percentage of recovery calculated as: (concentration observed in sample with added analyte Ϫ concentration observed in plasma without added analyte) ϫ 100%/(concentration added). Five microliters of plasma were analyzed for TNF-␣, IFN-␥, and MCP-1 assays, 5-25 L for all others. Assays were performed on 3 separate days, except for IL-5 and MIP-1␣ (once) and RANTES, which was not done because the basal concentration of this analyte in plasma is Ͼ1 g/L (see Table S1 in the online Data Supplement). b Mean LOD from calibration curves by use of 80-L calibrators performed on n separate days. LOD (also called limit of the blank) was calculated as the point on fitted calibration curves yielding a signal 2 SDs above assay background measured in the absence of antigen. analyte at basal concentrations of 100 ng/L. As expected, as analyte concentrations increased, within-and betweenday imprecision decreased. The CVs of these samples, when assay dilution was accounted for, were consistent with the low (ng/L) LOQ estimated for each SMIA.
Highly sensitive and precise SMIAs with excellent recoveries for several other analytes were also developed ( Table 1 and Table S1 in the online Data Supplement). Of the SMIAs tested, recoveries of analyte added to plasma were between 80% and 129% (Table 1) , and in most cases CVs were Ͻ20%.
These results illustrate that highly sensitive SMIAs can be developed for human plasma to precisely quantify cytokines and chemokines with good recoveries. Although comparisons with other detection platforms are difficult to make, the sensitivities, recovery, and precision of the SMIAs reported here rival those achieved in multiplex cytometric bead immunoassays and conventional ELISAs for cytokines (see (9 -11 ) and Table S1 in the online Data Supplement).
Efforts are currently underway to optimize assay performance and to capitalize on the miniaturization made possible by the single-molecule approach. On the basis of the molecular weights of the analytes tested here (7.8 -17 kDa), the observed LODs of 0.10 -1.2 ng/L correspond to 7.1-154 fmol/L of analyte, values well above the detection limits of the instrument for reporter molecules (Ͻ3 fmol/ L). Thus, there is considerable room for improving the LODs, which could be achieved by reducing assay background or by increasing sample enrichment during the assay, as follows. First, because nonspecific binding of reporter molecules resulted in a background of approximately 2-20 bins/s above the typical buffer background, which corresponds to approximately 10 -100 fmol/L of SA-A647 molecules (see Fig. S1A in the online Data Supplement), background could be decreased by as much as 10-fold. Second, the 2-to 5-fold enrichment of sample, which is brought about by eluting reporter molecules into 20 L, could be increased approximately 10-fold by reducing the elution volume to match the few microliters required for a typical 36-s sample reading time. Overall, these improvements could bring about the 2-to 30-fold improvements in assay sensitivity to meet the detection limits governed by the single-molecule analyzer. We anticipate that because of its requirement for relatively small sample volumes, this approach may have its greatest impact as a tool for discovering biomarkers, especially in cases involving scarce clinical samples. Human plasma is a complex fluid that contains more than 3000 individual proteins and peptides in quantities ranging from nanograms to tens of grams per liter (1, 2 ) . The plasma proteome and peptidome (3 ) hold great promise for disease diagnosis and therapeutic monitoring (4, 5 ) . In recent years proteomics has focused primarily on analysis of low-abundance proteins by use of high-resolution methods such as 2-dimensional electrophoresis (6 ) and mass spectrometry (7 ) . These methods have identified changes in the composition of low-abundance proteins and peptides in plasma that correlate with particular diseases. Typically no single protein emerges from such analyses as a wholly reliable biomarker. Instead changes in the pattern of proteins and peptides often serve as the best diagnostic indicator for a particular disease. In addition, many components of the peptidome were found to be complexed with more abundant serum proteins, especially human serum albumin and immunoglobulins. These findings led to the concept of the "interactome" (8 ) .
Currently, the routine clinical laboratory procedures that are used to assess major components of the proteome include protein electrophoresis (PE) and immunofixation electrophoresis. Modern differential scanning calorimetry (DSC) provides a direct means for detecting what is perhaps the most fundamental property of biochemical reactions, heat changes, and can reliably measure heat changes of 0.1 cal. In a typical DSC experiment, an aqueous solution of protein is heated at a constant rate in the sample cell alongside an identical reference cell that contains only the solvent (buffer). Thermal balance between the sample and reference cells is maintained by electrically powered feedback heaters. Any chemical process in the sample cell that absorbs or releases heat results in a thermal imbalance. The power applied by the feedback heaters provides a direct measure of heat capacity changes accompanying thermally induced denaturation and dissociation reactions and is recorded as a thermogram in the form of excess specific heat capacity vs temperature. Here we present preliminary data demonstrating that DSC provides a new method for studying the plasma/serum proteome and generates unique signatures for samples from healthy and diseased individuals.
Plasma samples from patients with cervical cancer and moderate cervical dysplasia [cervical intraepithelial neoplasia (CIN) category II] were obtained from the Gynecological Cancer Repository of the James Graham Brown Cancer Center. Normal plasma samples were purchased from Innovative Research, and plasma samples from patients with other diseases were purchased from BBI Diagnostics. Samples were stored at Ϫ80°C before analysis. Pure human plasma proteins were purchased from Sigma-Aldrich and Calbiochem. Samples (100 L) were dialyzed for 24 h at 4°C against 10 mmol/L potassium phosphate, 150 mmol/L NaCl, and 3.8 g/L sodium citrate, pH 7.5, to ensure complete solvent exchange. Samples were then filtered through 0.45-m cellulose acetate filters, diluted 25-fold with the dialysis buffer, and run (1-2 h) in a MicroCal capillary DSC to obtain a thermogram. The total protein (TP) concentration of the processed samples was measured by the bicinchoninic acid method (Pierce). Thermograms are plotted as excess specific heat capacity (cal/°C ⅐ g) vs temperature. We also performed PE on the samples (Helena Laboratories). In this study we used only frozen and thawed plasma samples, but we found no significant differences between fresh and frozen plasma or between plasma and serum except for the lack of fibrinogen in the latter (see the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/issue11). We used Origin 7.5 software (OriginLab) to calculate 2 thermogram variables, the area (A) and the 1st moment (M 1 ). M 1 is approximately the weighted center of the thermogram and is calculated as ͐Tf(T)dT.
The thermogram of a sample from a patient with stage IVB cervical cancer is shown in Fig. 1 along with the mean of 15 normal samples. The shaded region around the normal thermogram indicates the SD at each temperature. The 15 normal samples had a mean A of 5.04 cal/g (SD 0.25, CV 5.0%) and a mean M 1 of 67.8°C (SD 0.59, CV 0.86%). In addition, 24 h after obtaining the thermograms shown, we reanalyzed 1 of the normal samples and the cervical cancer patient sample shown in Fig. 1 (samples were stored at 5°C before the 2nd analysis). The A in the 2 samples increased 7.8% and 2.3%, respectively, which is comparable to the SD obtained for the mean of 15 normal samples, and the M 1 increased slightly, by 0.36% and 0.33%, respectively. The patient sample thermogram was markedly different from that of the normal sample. The area of the patient sample (4.91 cal/g) was within the reference interval, but the M 1 (69.7°C) was abnormally high. From thermograms of pure proteins (see the online Data Supplement) we have begun to identify some peaks. The major peak in the normal thermogram at 63°C is apparently due to albumin, and the small peak at 51°C is due to fibrinogen. In the cervical cancer patient thermogram, the signal from albumin appears to be greatly decreased or shifted to higher temperatures. The albumin concentration of this sample was within the reference interval, and the PE pattern was remarkable only for anincreased gamma globulin fraction (see the online Data Supplement). Therefore, the albumin peak appears to have been shifted, perhaps because of stabilization by bound ligands. The peak at 61°C revealed by the shifted albumin appears to be haptoglobin. We ran thermograms (data not shown) on additional plasma samples from patients with CIN II and early stages of cervical cancer. Samples from patients with CIN II (n ϭ 4) had slightly abnormal thermograms. Samples from patients with early stage cervical cancer (n ϭ 3) had moderately abnormal thermograms with a slight degree of albumin shifting. Compared with thermograms of samples from healthy individuals, thermograms of samples from diseased patients showed distinctive shifts as the disease progressed from CIN II, through early stage cervical cancer to the critically ill stage IVB cervical cancer (Fig. 1) . Compared with the DSC thermograms, PE patterns showed only subtle changes throughout the progression of the cancer.
We also ran DSC on 1 plasma sample each from patients with Lyme disease (LD), rheumatoid arthritis (RA), and systemic lupus (SL). The thermogram of the LD sample was markedly abnormal, resembling the cervical cancer IVB pattern, but with a smaller haptoglobin peak. The thermogram of the RA sample was similar to the thermograms of the CIN II sample, but slightly more abnormal. The SL thermogram was also similar to the cervical cancer IVB thermogram, but with an increased haptoglobin peak. PE patterns for these samples were generally unremarkable. PE results showed that the LD sample had a low TP and slightly low gamma globulin fraction, the RA sample was completely normal, and the SL sample had a low TP and gamma globulin fractions. Also, the PE pattern of the SL sample had a prominent peak on the cathodic side of the ␣ 2 -globulin fraction where haptoglobin migrates. This result in the PE was consistent with the increased haptoglobin peak in the thermogram, but insufficient to cause the ␣ 2 -globulin fraction to be above the reference range.
The thermogram provides a specific signature for each sample, reflecting the protein composition of the sample, and thus offers a unique window and physical basis with which to view the plasma proteome. Every protein has, under a given set of buffer conditions, a characteristic denaturation thermogram that is unique and provides a fundamental thermodynamic signature for that protein. A primary DSC thermogram is an extensive property of a protein solution and as such is directly proportional to the mass of the protein in solution. The thermogram of a protein mixture will be the sum of all of the individual protein thermograms, weighted according to the mass of each component. Moreover, DSC is exquisitely sensitive to binding interactions. When a ligand binds to a protein, it stabilizes that protein, raising its melting temperature. Proponents of the interactome concept argue that in disease states, low molecular weight proteins or peptides unique to that disease increase in concentration in plasma, forming complexes with the more abundant proteins, particularly albumin and the immunoglobulins (8 ) . Such interactions would alter the denaturation thermograms of those proteins, producing characteristic changes in observed thermograms relative to the normal signature (Fig. 1) . Changes in DSC thermograms are likely to be far more dramatic than are changes in concentration that are observed by chemical and immunochemical methods and PE.
We conclude that DSC of plasma samples may become a useful diagnostic procedure. Ongoing studies will explore the range of thermogram patterns in a wide variety of diseases. In addition, a greater number of samples from disease-free individuals will be examined to more rigorously define a normal thermogram. The effects of specific interactions with small protein or peptide components and other ligands (e.g., bilirubin) that may be present in plasma/ serum in the disease state, as well as protein modifications (e.g., glycation), will also be examined. We will correlate the results from our calorimetric assay with clinical diagnoses as well as the results from PE and immunochemical assays for specific plasma proteins. When discrepancies are found, diseased tissues will be examined histologically to confirm or refine the clinical diagnoses.
Grant/funding support: This work was supported by National Cancer Institute Grant R44 CA103437 (to J.B.C. More recently, the automation of all assay steps including sample preparation has become feasible, and fully integrated, high-performance nucleic acid analyzers (3 ) have become commercially available. However, the high cost of analyzers and assays still limits their routine use.
To facilitate the everyday use of PCR, we have developed a new instrument platform, GenomEra TM , which combines rapid thermal cycling (4 ); low-cost plastic reaction vessels (4 ); a homogeneous, dual-label assay technology based on end-point time-resolved fluorescence (TRF) detection; software with an intuitive user interface; and ready-to-use dry-reagent reagent sets (5 ) . The GenomEra assay chips are made of polypropylene and metal foil, allowing optimal optical characteristics and a high speed of thermal transfer. The foil acts as a mirror to enhance the intensity of the long-lifetime fluorescence measured from the closed reaction vessels. Thermal cycling in the GenomEra instrument is based on a conveyor that transfers the reaction chips cyclically between thermal blocks maintained at constant temperatures. Combined with the assay chips that are laminated with metal foil, the rate of temperature change inside the reaction chamber can be highly accelerated compared to conventional 1-block instruments. In addition to the denaturation, annealing/ extension, and measurement blocks, "hot" and "cold" blocks set to more extreme temperatures are used to further increase the speed of temperature change. The automated platform is intended for rapid, sensitive, small-scale analysis of any nucleic acid that can be detected by PCR. The target-specific reagents are predispensed and dried inside the assay vessels, and after the user has added the preprocessed sample (various sample preparation methods can readily be used), the analysis is performed automatically starting from the selection of an applicable temperature profile and ending with the reporting of unambiguous qualitative results.
We developed a homogeneous GenomEra PCR assay for Borrelia burgdorferi sensu lato, a species complex of tick-transmitted spirochetes causing Lyme borreliosis (6 ) . The end-point detection of PCR amplification is based on competitive hybridization (7, 8 ) . In the dual-label assay, terbium (Tb) is used to detect amplification of the target sequence, and europium (Eu) the amplification of the internal amplification control (IAC), which minimizes the possibility of false negative results. All oligonucleotides were obtained from Thermo Fisher Scientific. The Borreliaspecific primer sequences were as described by Schwaiger et al. (9 ) , and the label-and quencher-probe sequences were 5Ј-aminolink C6-TGCTACAACCTCATCTGT CATTG-3Ј and 5Ј-CAATGACAGATGAGGTTGTAGCA Dabcyl-3Ј, respectively. For the IAC, the primers were as described by Nurmi et al. (10 ) , and the label-and quencher-probe sequences were 5Ј-aminolink C6-CCT TCTGAGGGTGATTGCG-3Ј and 5Ј-GCGAATCACCCT CAGAAGG-Dabcyl-3Ј, respectively. nmol/L quencher probe) and IAC-specific (0.15 mol/L primers, 10 nmol/L label probe, 100 nmol/L quencher probe) oligonucleotides, and 10 000 copies of the IAC were dispensed onto the plastic reaction chips. The heatstable polymerase in a buffer containing 1 g/L BSA was added in a separate drop, and the reagents were dried under vacuum. The chips were then laminated with aluminum foil, barcoded, and stored with desiccant in sealed aluminum foil bags at room temperature until use. According to our stability studies, the dry-reagent assay chips are stable at room temperature for 4 months.
To start an assay, 30 L of sample (Borrelia cells diluted in water) was dispensed in the chip. The chips were then transferred into the GenomEra nucleic acid analyzers 4 at a time, and the applicable temperature profile was automatically selected and initiated by the instrument based on the barcode on the analyte-specific chips. Inside the instrument, the chips were irreversibly sealed with heat and cycled between thermal blocks maintained at constant temperatures. After PCR (initial denaturation at 100°C for 115 s, followed by 45 cycles of 27°C for 1.7 s, 60°C for 16 s, 108°C for 5.5 s, and 100°C for 3 s), all oligonucleotides present in the mixture were denatured (108°C for 10 s, 100°C for 60 s). The temperatures given above refer to the settings of the heat blocks, not to the temperatures inside the reaction vessels. Subsequently, TRF signals were measured twice using the built-in fluorometer. The result value was then calculated as the ratio of H ϫ 100:D, in which H is the signal obtained from a hybridized probe (measured after 120 s at 50°C) and D the signal obtained from a denatured probe (measured after the final denaturation step and 3.8 s at 50°C) (12 ) . The total turnaround time of the assay was 42 min.
The reproducibility of the system was studied by preparing a panel of 20 test samples (8 negative and 12 positive controls enriched with 20, 100, or 500 Borrelia cells) that was analyzed by 3 individual operators using 4 instruments; each operator running the samples on a different day ( Table 1) . The results were automatically deduced by the software based on the cutoff values embedded in lot-specific barcodes. The results obtained from individual reaction vessels were not compared to any control samples in the same assay run. Typical of end-point PCR results, the CV was high, especially in samples enriched with target cells, because the end-point reading is not a quantitative measure of the initial amount of template in the sample. With the lot-specific cutoff values of 31 (mean result value of 20 negative controls ϩ 4 SD) and 38 (mean result value of 20 negative controls ϩ 7 SD) for the target and the IAC, respectively, result interpretation is straightforward, and a calculated result above the cutoff accurately indicates successful amplification of the sequence of interest (target, IAC, or both). For a positive result, a result value only above the target cutoff value is required, because the competition for reagents may suppress the amplification of the IAC. In this study, no operator effects were observed; each of the 3 users obtained an identical and 100% accurate set of qualitative results. The detection limit of the assay, corresponding to the cutoff value of 31, was 5 Borrelia cells per reaction. For simplicity, however, the numerical results are usually not visible to the operators; instead, only the qualitative conclusion of the assay run (i.e., target detected/not detected) is reported. If neither of the 2 sequences can be detected because of sample-derived PCR inhibition, the result is reported as "inconclusive".
Increasingly sophisticated and automated nucleic acid detection methods are being developed at an advancing pace. Because all of the pioneering instruments are based on the real-time PCR methodology (2 ), the GenomEra platform can be viewed as an expedient alternative in settings in which quantitative answers are not required. The instrument is controlled by user-friendly software that guides the operator through assay initiation and, after completion of the assay, reports the results as simple answers instead of fluorescence readings or amplification graphs. All analytical results are automatically archived in a database that can be browsed at any time.
GenomEra is the only PCR instrument available to date that is capable of exploiting the excellent sensitivity of TRF in multiplex, homogeneous nucleic acid detection. Use of the lanthanide chelates of Eu and Tb allows elimination of the rapidly decaying background fluorescence originating from plastic ware, light scattering, and sample components. Furthermore, because of the sharp and nonoverlapping emission profiles of the lanthanides, TRF readily facilitates multiplex assays. Although the fluorescence reader of the instrument is specifically designed for assays that use TRF, the instrument can also be used to measure the more commonly used short-lifetime fluorophores, such as FAM and SYBR ® Green. The TRF measurement mode leads to an up to 100-fold improved assay sensitivity compared to the latter label technology (10 ) . Because the results are deduced by lot-specific cutoff values manufactured by the software, there is no need to run separate negative control samples in each batch of analysis or to perform real-time measurements. To eliminate variation originating from sample pretreatment, we chose not to use complex clinical sample matrices in the current study. Nevertheless, the assay can readily be combined with a range of specimen treatment methods, including filtration and immunomagnetic separation (data not shown).
In conclusion, we have developed an automated, homogeneous DNA-testing platform to simplify and speed up nucleic acid assays and to facilitate their routine use. The platform is specifically designed for users with minimal expertise in PCR chemistry. The platform has a high potential for adaptation to any application in nucleic acid There is a need for rapid nucleic acid amplification and detection technologies suitable for point-of-care settings. PCR-based molecular diagnostics, portable thermocyclers, and rapid microfluidic techniques are emerging technologies (1 ) , but the use of isothermal nucleic acid amplification would make less demanding instrumentation feasible. Most isothermal methods reported to date (2-7 ) require reaction times Ͼ30 min. In this study, we describe very rapid isothermal DNA amplification through EXPAR (exponential amplification reaction) (8, 9 ) coupled with visual colorimetric detection facilitated by aggregation of DNA-functionalized gold nanospheres (10 -12 ) applied to a genomic sequence derived from herpes simplex virus (HSV)1.
Rapid detection of HSV infections is important in HIV-positive and immunocompromised individuals (13, 14 ) , pregnant women, and newborns (15 ) . PCR-based assays are superior to viral cultures and immunoassays for the diagnosis of HSV infections from cerebrospinal fluid (16 ) and genital, oral, and topical swabs (17) (18) (19) (20) . New rapid, low-cost molecular diagnostic tools can enable broad-based testing of at-risk populations, providing effective patient treatment and preventing further disease spread.
EXPAR (8, 9 ) isothermally amplifies a short oligonucleotide trigger 10 6 -to 10 9 -fold in Ͻ10 min. EXPAR occurs at 55°C, permitting activity and stability of the polymerase and nicking endonuclease involved in the reaction (9 ) . Trigger X primes an amplification template containing 2 complimentary XЈ sequences and enables generation of the nicking enzyme recognition and cleavage site (see Fig.  S1 in the Data Supplement that accompanies the online version of this Abstracts of Oak Ridge Posters at http:// www.clinchem.org/content/vol53/issue11). Trigger extension and single-strand nicking create another trigger oligonucleotide, which dissociates from the amplification template. Through repeating cycles of elongating and nicking, the trigger is linearly amplified. Newly formed triggers prime other amplification templates, causing exponential amplification. The progression of EXPAR can be monitored in real time using SYBR Green. As an indirect measure for trigger amplification, the sigmoidal increase in fluorescence intensity reflects conversion of template into the partially double-stranded trigger-producing form, (see Fig. S2 in the online Data Supplement). The time at which each amplification curve reaches its inflection point is linearly correlated to the logarithm of the starting trigger concentration (see Fig. S3 in the online Data Supplement), similar to the correlation between cycle threshold and target DNA concentration in real-time PCR.
Despite the positive attributes of EXPAR, the detection limit of this method is currently high because of nonspecific background amplification. Investigations are ongoing to determine the nature of this amplification observed in the absence of trigger, and our data suggest that unconventional DNA synthesis may be involved (unpublished data). The timing of background amplification depends on the template sequence and mastermix composition. For suitable EXPAR templates, trigger concentrations of 10 fmol/L (1.8 ϫ 10 5 copies in a 30-L reaction volume) can be reproducibly differentiated from background, using as a metric a Ն10% difference between the inflection points of the real-time fluorescence curves for the trigger-containing (positive, P) and no trigger-con- Although such low limits of detection are not routinely attainable, we are optimistic that through systematic assay optimization it will be possible to perform EXPAR in a robust manner with PCR-like sensitivity.
To facilitate visual detection, we have developed a 2-stage EXPAR amplification reaction, coupled to aggregation of DNA-functionalized gold nanospheres through a bridging reporter sequence (9 ) . DNA nanosphere aggregation causes a red-to-blue color change attributable to a shift in plasmon resonance (10 -12 ) . We previously re- (B), negative ion mode liquid chromatography/electrospray ionization TOF mass spectra of fingerprinting reactions performed without coupling to exponential amplifications, i.e., involving a mastermix containing enzymes, deoxyribonucleotide triphosphates (dNTPs), and other general reagents plus either 1 nmol/L HSV1-Vector1 (top) with a 273-bp insert derived from HSV1 genomic DNA (Table 1 , sequence 1) or no vector (bottom), but no externally added template or trigger oligonucleotides. In the presence of 1 nmol/L HSV1-vector1 approximately 80 nmol/L of trigger HSV1-1a (Table 1, (Table 1 , sequences 4 and 5) was incubated at 55°C for 4 min or 6 min. The reaction was quenched by the addition of a nanosphere detection reagent containing 2 sets of Au nanospheres, respectively, functionalized with the 5Ј and 3Ј nanosphere probe sequences (Table 1, ported that 2-stage EXPAR coupled to DNA-nanosphere aggregation enables detection of 100 fmol/L trigger oligonucleotide in Ͻ10 min. Through continuing optimization, we can now reproducibly detect 10 fmol/L trigger (60 000 copies in 10 L) with amplification times of 3.5 or 4 min. We have occasionally achieved low copy number detection limits (1 amol/L, 6 copies in 10 L; see Fig. S5 in the online Data Supplement), but variability in assay performance exists at starting trigger concentrations Ͻ10 fmol/L. To be useful for clinical diagnostics, this assay must be coupled with trigger generation from a genomic target DNA sequence. One approach for trigger generation, called fingerprinting, is based on adjacent nicking enzyme recognition sites within genomic DNA (Fig. 1A) . When these sites are oriented head-to-head, both strands are cut by the nicking enzyme, and the genomic DNA dissociates, creating templates for 2 complementary triggers that are linearly amplified through consecutive cycles of polymerase extension and single-strand nicking, (analogous to linear amplification within EXPAR; see Fig. S1 in the online Data Supplement). Fingerprinting can be performed isothermally at the same temperature and in the same mastermix as EXPAR, without additional reagents. Differential HSV diagnosis requires distinction from other pathogens and from human genomic DNA. On the basis of in silico sequence analysis, HSV1 fingerprinting produces 14 trigger oligonucleotides without overlap with the predicted trigger sequences of the other human herpes viruses (see Table S1 in the online Data Supplement), other potentially interfering pathogens, or of human genomic DNA.
In this proof-of-principle study, we targeted a 28-mer fingerprinting site within the open reading frame of the nuclear protein UL3 (Human herpesvirus 1) gene UL3 containing 2 GAGTC sites oriented head-to-head. We have performed fingerprinting with a preliminary model system, a pUC19 vector with a 273-bp HSV1-derived insert that contains the targeted UL3 fingerprinting site (Table 1 , sequence 1) and enables generation of the complementary trigger oligonucleotides HSV1-1a and HSV1-1b (Table 1 , sequences 2 and 3). Of these 2 triggers, we have selected HSV1-1a for subsequent assay design. This vector model system (termed HSV1-vector1), which can be obtained inexpensively in pure form and at high concentrations, serves as a practical intermediate step in establishing the assay. The same reaction applies in principle to trigger generation from HSV1 genomic DNA.
Through negative ion mode liquid chromatography/ electrospray ionization TOF mass spectrometry, we verified that HSV1-1a is generated via fingerprinting in the presence of 1 nmol/L HSV1-vector1. No product peaks were observed in the absence of the vector, a finding that corroborates the specificity of the reaction (Fig. 1B) . Because fingerprinting involves linear amplification only, nanomolar starting concentrations of vector are required without coupling to EXPAR. To improve this detection limit, we coupled fingerprinting with EXPAR by including the appropriate XЈ-XЈ template in the reaction mixture (Table 1 sequence 4, Fig. 1C ). According to the SYBR Green fluorescence data (Fig. 1D ), fingerprinting coupled with single-stage EXPAR can differentiate 1 pmol/L HSV1-vector1 from nonspecific background amplification, with marginal differentiation at the 100 fmol/L level, a 10 3 -to 10 4 -fold lower detection limit than fingerprinting alone. We coupled trigger generation and amplification with visual colorimetric detection (Table 1 sequence 6, Fig. 1E ) by including the vector and both templates (XЈ-XЈ and XЈ-YЈ, Table 1 sequences 4 and 5) in the reaction mixture. After amplification at 55°C, the reaction was quenched by adding a DNA nanosphere detection reagent, which contains 2 sets of gold nanospheres bearing the 5Ј and 3Ј probes, respectively (Table 1, sequences 7 and 8). During incubation at room temperature for 2 min, reporter Y generated through 2-stage EXPAR hybridizes to and -GGA TCC CTG GTC TCA TAC GGG TCG GTG ATG TCG GGC GTC GGG GGA GAG GGG GTT CCC TCT  GCG CTT GCG ATT CTA GCC TCG TGG GGC TGG ACG TTC GAC ACG CCA AAC CTC GAG TCA GGG  ATA TCG CCA GAT ACG ACT CCC GCA GAT TCC ATT CGG GGG GCC GCT GTG GCC TCA CCT GAC  CAA CCT  TTA CAC GGG GGC CCG GAA CGG GAG GCC ACA GCG CCG TCT TTC TCC CCA ACG CGC GCG GAT  GAC GGC  CCG CCC TGT ACC GAC GGG CCC AAG CTT-3Ј  2  Trigger HSV1-1a  5Ј-CTG GCG ATA T-3Ј  3 Trigger HSV1-1b 5Ј-ATA TCG CCA G-3Ј aggregates the DNA nanospheres. After being spotted on a C18 reverse-phase silica thin-layer chromatography plate, aggregated nanospheres yield a blue spot (positive) and monodisperse nanospheres yield a red spot (negative). We are currently able to detect 1 pmol/L HSV1-vector1 (6 ϫ 10 6 copies in a 10 L-reaction volume) after 4-min amplification at 55°C (Fig. 1F) with good intra-and interassay reproducibility and 4-min amplification time at 55°C. These results are based on 3 different experiments conducted on 3 different days, each in duplicate. Longer amplification times produce nonspecific background as displayed by the "No Vector" negative control. The 2 additional controls labeled positive and negative signify that DNA nanospheres are stable under the reaction conditions and aggregate in the appropriate manner.
In conclusion, we have demonstrated detection of an HSV1-derived genomic sequence through a simple, rapid molecular diagnostic assay that can be performed in Յ10 min and requires only a heating block and minimal consumption of reagents and supplies, characteristics that make this method suitable for point-of-care and limited resource settings. We are performing systematic assay optimization to ensure sensitivity, reproducibility, and robustness required for clinical diagnostic applications, and are investigating the cause of nonspecific background amplification. At a minimum, we are targeting a limit of detection appropriate for diagnosis of HSV from swab samples of herpetic lesions, reported to contain on average 8 ϫ 10 4 virus particles/mL lysis buffer (19 ) . The proof-of-principle results presented were obtained using a plasmid vector model system with HSV1 insert. We are in the process of establishing the reaction with DNA isolated from clinical samples, and expanding the assay to HSV2. Fingerprinting is the simplest approach for trigger generation from genomic DNA, but has limitations. We are therefore also exploring alternative probe-based trigger generation reactions that can interrogate arbitrary genomic DNA or RNA sequences. Hybridization of double-stranded DNA with nucleic acid probes is hampered by competition between the complementary nontarget strand and the probe (1 ). This competition is stronger with surface-bound probes that expose a target strand with a long dangling end toward the media (2, 3) . This situation is more problematic in infectious disease diagnostics, which requires high sensitivity, sometimes as low as 1 genome copy. Microarray integration into microfluidic systems results in increased speed and sensitiv-ity while allowing automation of the whole hybridization process (4 ) and could lead to the development of point-ofcare diagnostic devices. Actual limitations of diagnostic microarrays include the design of ultrasensitive capture probes that are highly specific and discriminant. Some techniques have been developed to produce single-stranded DNA targets for sequencing and hybridization, but these methods may necessitate additional steps or modification of the target strand or have poor sensitivities (5-8) . Degradation of the complementary strand can alleviate competition problems and allow more flexible probe design for the target strand. Therefore, we developed a simple 5-min method for rapid single-step selective digestion of the complementary strand with lambda exonuclease, which leads to increased hybridization signals and improved differentiation of singlenucleotide polymorphisms (SNPs) on DNA microarrays.
Cy3-labeled primers were used to generate the target strands, and phosphorylated primers were used to generate the complementary strands. Nonphosphorylated primers were also used to verify the protection provided by the Cy3-labeled primers. All oligonucleotides were purchased from Integrated DNA Technologies. Table 1 in the online Data Supplement that accompanies the online version of this Abstracts of Oak Ridge Posters at http://www.clinchem. org/content/vol53/issue11), and 0.05 kU/L KlenTaq (AB peptides).
Amplicons from N. meningitidis (42.1 mg/L), L. monocytogenes (37.1 mg/L), and C. krusei (42.5 mg/L) were digested with 10 units of lambda exonuclease (New England Biolabs) at 37°C in the PCR buffer described above for 5 min unless otherwise noted. Nondigested control amplicons were denatured at 95°C for 5 min and then cooled on ice for 3 min, whereas digested products were directly used for microarray hybridization without prior heat treatment. Digestions were monitored with capillary gel electrophoresis performed on the Bioanalyzer 2100 (Agilent Technologies). For the comparison between C. krusei phosphorylated (7.9 mg/L) and nonphosphorylated (7.6 mg/L) complementary strand digestion, amplicons were purified with the QIAquick PCR Purification Kit (QIAGEN) and then digested in lambda exonuclease buffer for 30 min. Microfluidic hybridization experiments were conducted with nonpurified amplicons from L. monocytogenes (23.1 mg/L) digested with the exonuclease for 5 min. Oligonucleotide probes (see Table 2 in the online Data Supplement) with a 5Ј amino-linker were suspended in Micro Spotting Solution Plus (TeleChem International) and spotted at 30 mol/L on Super Aldehyde slides (Genetix) with a VIRTEK SDDC-2 Arrayer (Bio-Rad Laboratories).
All amplicons were subjected to hybridization at room temperature (22-25°C) in 6ϫ saline-sodium phosphate-EDTA (SSPE; EMD Biosciences), 0.03% polyvinyl-pyrrolydone (Sigma), and 30% formamide (Sigma). Passive hybridizations were conducted with 20-L volumes containing 1.75-10 mg/L of target amplicons. Passive hybridization (1 h) was performed with a glass lifterslip (Erie Scientific) apposed to the microarray slide. Active hybridization (5 min) was achieved with a compact discbased polydimethylsiloxane microfluidic device, as previously described (4 ) . Washing was performed in 0.2ϫ SSPE ϩ 0.1% sodium dodecyl-sulfate, followed by rinsing in 0.2ϫ SSPE. Slides were scanned with a ScanArray 4000XL (PerkinElmer), and the hybridization signals were quantified with GenePix 6 (MDS Analytical Technologies). A Cy3-labeled control oligonucleotide (see Table 3 in the online Data Supplement) was used to validate the microarray subarrays. Subarrays with a median signal of 5000 fluorescence units or more for the control oligonucleotide were considered valid, and those with lower signals were discarded. All hybridization signals were corrected for background (the median background was 100 fluorescence units or less) and were then expressed as a percentage of the control oligonucleotide signal.
Hybridization of amplicons from N. meningitidis, L. monocytogenes, and C. krusei digested directly in PCR buffer with the lambda exonuclease all yielded signal enhancements (up to 14.5-fold; Table 1 ). Microfluidic electrophoresis has shown that around 90% of doublestranded DNA with phosphorylated complementary strands and Cy3-labeled target strands was digested compared to an undigested control (data not shown).
To monitor the influence of the Cy3 label on lambda exonuclease digestion, C. krusei amplicons produced with Cy3/phosphorylated or Cy3/nonphosphorylated primers were purified and then digested with lambda exonuclease. Passive 1-h hybridization of the digested C. krusei amplicons with nonphosphorylated complementary strands yielded a significant hybridization signal increase of 5-fold or more (Fig. 1A) . A higher signal increase (15-fold) was obtained by digestion of the phosphorylated complementary strand with lambda exonuclease. Selective digestion of the complementary strand yielded a strong hybridization signal with the C. krusei-specific capture probe ECkruH715, whereas no signal was measured with nondigested control amplicons (Fig. 1A) . Digested amplicons yielded higher hybridization signals, facilitating the differentiation of SNPs, as exemplified by the signal with the perfectly matched C. krusei probe ECkruH703, which is at least twice as strong as the signal with the singlemismatched Candida albicans probe ECalbH596. Nondigested amplicons could not distinguish this SNP.
For active hybridization, amplicons were introduced into the microfluidic unit juxtaposed to a microarray slide (4 ) . Microfluidic hybridization of the digested product showed a 6-to 9-fold increase in the measured hybridization signals compared to nondigested control amplicons (Fig. 1B) .
Selective direct digestion of complementary strands with lambda exonuclease in PCR buffer yielded up to a Clinical Chemistry 53, No. 11, 2007 14.5-fold increase in microarray hybridization signals compared to nondigested control amplicons. Because the complementary strand is eliminated from the hybridization material, little or no interaction with the dangling end occurs, thus preventing displacement of the target strand hybridized to the microarray capture probe (2 ) .
Several investigators have used exonuclease digestion of the complementary strand to produce single-stranded DNA targets for hybridizations (8 -16 ) . However, these methods are more cumbersome than our 5-min method because they require additional steps, longer digestion times (15-45 min), and in some cases, more complex modifications of the target strand. Although most investigators have suggested that single-stranded DNA targets can yield better hybridization signals, only a few (9, 10 ) directly compared digested products with nondigested controls. Under optimal conditions, investigators observed at most a 2-fold increase in hybridization signals with purified DNA targets compared to a 14.5-fold increase with our simple 5-min method.
We have investigated how the presence of a Cy3 label at the 5Ј end of the target strand influences lambda exonuclease digestion. Because the lambda exonuclease has 20ϫ more affinity for a phosphorylated 5Ј end than a hydroxylated 5Ј end (17 ), we compared the digestion of both of these substrates paired with a 5Ј Cy3-labeled target strand. We conducted the digestion in lambda exonuclease buffer at 37°C for 30 min for optimal enzymatic activity. The combination of a 5Ј Cy3-labeled target primer with a phosphorylated complementary strand yielded the best signal increase. Amplicons produced by a Cy3-nonphosphorylated primer combination also yielded an increased hybridization signal, suggesting that lambda exonuclease has less affinity for the Cy3-labeled 5Ј end than for the hydroxylated 5Ј end, thereby somehow protecting the target strand. Competition for the target strands between the complementary strands and the capture probes during passive hybridization has been previously reported by our group (2 ) . Although hybridization time is shortened with the microfluidic platform (4 ) and the hybridization kinetics is increased, competition between complementary strands and capture probes also occurs. Digestion of the complementary strands by lambda exonuclease resulted in a 6-to 9-fold increase of the hybridization signals obtained with the microfluidic platform compared with the nondigested control amplicons. This finding confirms that the generation of single-stranded DNA targets results in increased fluorescence signals both with passive and active microfluidic microarray hybridizations.
The 1-step digestion procedure presented here increases hybridization signals and facilitates SNP differentiation without any further modification for protection of the target strand, such as incorporation of phosphorothioate nucleotide analogs (8 ) . Protection of the target strand likely comes from the Cy3 label used for microarray detection as suggested above. Increased hybridization signal allows the use of more stringent washing conditions along with the use of shorter microarray probes for better SNP differentiation. This digestion step eliminates the need for high-temperature denaturation and can be performed directly in a standard PCR buffer. The simplicity of our digestion and hybridization procedures make them amenable to integration into fully automated compact diagnostic devices. Microfluidics-based lab-on-a-chip systems, which feature miniaturization of biological separation and assay techniques, are rapidly transforming biochemical analysis and high-throughput screening. Microfluidic system design requires expertise in materials, chemistry, biology, and engineering, and understanding the complex interplay between variables that influence and limit system performance is difficult without computational assistance. Modeling approaches based on 3-dimensional numerical simulations provide detailed information regarding spatiotemporal variations of the field variables but are computationally very expensive for system-level analysis. Design-modeling tools are needed that rapidly simulate the complex underlying phenomena such as electroosmosis, electrophoresis, sample dispersion, mixing, and biochemical reactions without significantly compromising accuracy (1) (2) (3) (4) (5) . In addition, these design tools must be easily usable by the microfluidic community, which comprises scientists and engineers from a variety of disciplines. To meet these challenges, we developed integrated design software that allows rapid layout of microfluidic Clinical Chemistry 53, No. 11, 2007 channel networks, fast system performance simulation using a system solver, and the ability to easily reconfigure chip layout to meet specifications. We illustrate the application of the software to improve the design for an electrokinetic immunoassay chip.
The software design follows a modified form of the traditional client-server architecture. The user interacts with a graphical user interface (GUI) front-end (client). Fig. 1 shows a screenshot of the GUI. The microfluidic lab-on-achip system is represented as a network of interconnected components that can be assembled from a component library. The sequence of operations required for the creation of the microfluidic network, analysis, and visualization of results using the GUI is as follows:
(1) Creation of the microfluidic network: The components (such as sample reservoirs, straight channels, bends, biosensors, and interconnects such as Y-, T-, and cross junctions) are selected from the component library and assembled into a network using a drag-and-drop method.
(2) Problem specification: Geometric properties for components (channel length, breadth, and depth, turn radius and angle, well diameter) and operating conditions (applied voltage and pressure, flow rate, and injected analyte concentrations, as appropriate for the problem under consideration) are specified for the components. The property database contains physicochemical property data for commonly used buffers, reagents, and analytes (density and viscosity of buffers; electrical conductivity, and electrokinetic mobility and molecular diffusivity of analytes) and is fully integrated with the GUI.
(3) Solution and visualization: The performance is simulated using the system solver, and the results are analyzed using the visualization toolkit, which allows the results from the simulation to be displayed in a variety of tabular and graphical formats.
The GUI employs the hierarchical model-view-controller (MVC) architecture (6 ) to achieve the user-friendliness, flexibility, and extensibility needed. MVC programming uses 3-way factoring, whereby objects of different software classes take over the operations related to the application domain (model), the display of the application's state (view), and the user interaction with the model and the view (controller). The MVC architecture is aimed at exploiting the benefits associated with modular components in the software. The GUI has been developed with the Java™ programming language using standard Java libraries and the included Swing toolkit (7 ) .
(4) System solver: The system solver uses a combination of various modeling approaches for a rapid simulation of the microfluidic chip performance. This mixed-methodology approach uses an integral method to simulate fluid flow and electric field, a method of moments-based analytical solution to compute analyte dispersion, and a Fourier series-based analytical solution to compute microfluidic mixing based on laminar diffusion. These disparate models have been integrated in the system solver and validated against both experimental data and detailed 3-dimensional numerical models. The system solver shows a substantial improvement in computational speed (2-4 orders of magnitude) over the 3-dimensional models without appreciably compromising accuracy (error Ͻ10%). Details of the models and validation studies have been described elsewhere (4, 8 -10 ) . A brief explanation of these models is given below:
Visualization Toolkit
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Layout Editor
• Fluid flow: Pressure-driven flow is calculated by solving the Navier-Stokes and continuity conservation equations in their integral forms. An implicit iterative numerical solution scheme based on the SIMPLE (semiimplicit method for pressure-linked equations) algorithm (11 ) is used. Details of the implementation are discussed elsewhere (8 ).
• Electric field: The electric current conservation law is solved at every component with a constitutive equation to compute currents and voltages. These equations are used to compute the electroosmotic and electrophoretic flow velocity.
• Analyte transport: An analytical model based on the method of moments approach has been developed to characterize the dispersion induced by combined pressure and electrokinetic-driven flow. In addition, the system solver uses a combination of numerical schemes and analytical approaches to simulate mixing due to laminar diffusion and biochemical reactions; specifically, the method of lines (MOL) and 2-compartment models for biochemical reactions, and a Fourier seriesbased model for analyte mixing.
We present the use of the microfluidic design software to improve the design of an electrokinetic microfluidic device for an on-chip assay of the drug theophylline (Th) in serum samples. The assay involves on-chip mixing of serum samples with a labeled tracer compound and reaction with a selective antibody. This reaction is followed by an electrophoresis-based separation step to isolate and quantify the reactants and products. This immunoassay method is appropriate for incorporation into a microfluidic format and allows for rapid separation, because of the short separation distances. Starting with the microfluidic device previously demonstrated (12 ), we applied the software to rapidly explore alternative design concepts to improve device performance and demonstrate the ability to create a lab-on-achip for a real clinical analysis using a simulation-based design approach. Similar analysis using an analog hardware description language (Verilog-A) has been previously reported (13 ) . The operation of the competitive immunoassay chip is a multistep process that includes (a) mixing of serum sample containing Th with fluorescein-labeled Th tracer (Th*), carried out in the microfluidic channel and based on laminar diffusion; (b) reaction of the resulting mixture with an anti-Th antibody (Ab), which allows Th and Th* to compete for a limited number of antibody-binding sites; (c) electrokinetic injection of the solution containing the Ab-Th* complex produced in the reaction, as well as the unreacted Th*, into the separation channel, where they are separated by electrophoresis; and (d) detection of the fluorescent species (Th* and Ab-Th*) by laser-induced fluorescence.
The chip layout was created in the layout editor, using the component library and the drag-and-drop methodology. The layout parameters (channel dimensions, connectivity) and operating conditions (voltages and concentrations) were specified, and the performance of the chip was simulated. All channels had a rectangular cross-section with a uniform depth of 20 microns. The original layout had channels with widths of 52-236 microns, and the same widths were used in the modified layout. Th and Th* in the sample were specified in the system design software as separate species with identical molecular diffusivity (3. (14 ) . The binding between Th and Ab was assumed to be irreversible and complete. An electric field of 770 V/cm was used for electrophoretic separation. The performance was characterized by the extent of mixing/ reaction and by the efficiency of separation, which is characterized by the separation resolution, peak height, variance, and time for separation. The layout was reconfigured using the layout editor to minimize the chip footprint. The modified layout (3.5 cm ϫ 3.5 cm) occupies Ͻ25% of the area of the original chip (7.6 cm ϫ 7.6 cm), and the time required for electrophoretic separation was decreased by more than 50% relative to the original design (12 ) , thereby decreasing the overall assay time. This reconfiguration decreased the separation resolution, but the resulting resolution was still sufficient to resolve the species bands while limiting the bandbroadening induced by dispersion. In addition, the signal amplitude increased by 11.5% and 5% for Ab-Th* and Th*, respectively. The degree of mixing for the antibody:
where y is the widthwise coordinate, w is the channel width, c is the concentration profile along the channel width, and c avg is the average concentration along the width, was also improved to 100%. The entire analysis (including layout generation and problem setup) was completed in approximately 4 h, more than 2 orders of magnitude faster than currently available techniques. The improvements are summarized in Table 1 . In retrospect, the original system was substantially overdesigned, a problem that is common to several microfluidic systems currently available today and is attributable primarily to a lack of design tools.
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In summary, the design software we describe is useful for estimating device performance and creating microfluidic chip layouts; these layouts can be rapidly modified to design chips that meet performance requirements. We used the software to improve the design of a microfluidic immunoassay chip. The resulting design occupied Ͻ25% of the area of the original chip, and the time required for electrophoretic separation was decreased by more than 50% relative to the original design, allowing for a faster assay. This process is more than 2 orders of magnitude faster than conventional design techniques and is ideally suited for design optimization of microfluidic lab-on-a-chip systems. (2 ) , and are more prone to oxidative stress (3 ). Small, dense LDL particles also have a prolonged plasma half-life because of their lower binding affinity for the LDL receptor (4 ). The presence of small, dense LDL particles in plasma is, therefore, considered to be proatherogenic.
Analytical methods for LDL size characterization are therefore expected to improve classification, diagnosis, and therapy of dyslipidemic patients. However, simple methods for routine LDL size measurement are not yet available. LDL size is mainly measured by nondenaturing PAGE (5 ), which is time-consuming and may be unsuitable for large numbers of samples. Easier methods for measuring LDL size have been proposed, including highperformance gel-filtration chromatography (HPGC) (6 ) . Both PAGE and HPGC can give accurate size estimations only if appropriate standards are available. Moreover, recent studies have shown that LDL particles may be discoidal, with diameter and height that are not significantly correlated (7 ) . PAGE and HPGC cannot give information on particle conformation.
Flow field-flow fractionation (FlFFF) is a separation technique in which macromolecules and particles are separated by the combined actions of an axial flow and a perpendicular cross-flow (8 ) . No stationary phase is present, and the separation mechanism is sufficiently gentle not to alter the native structure of proteins and protein complexes (9 ) . Proteins are fractionated according to their difference in diffusion, with retention time that is inversely proportional to the analyte diffusion coefficient.
In principle, with the use of FlFFF it is possible to obtain the hydrodynamic radius (R h ) of proteins from their retention time values. A microchannel, prototype variant of FlFFF, the hollow-fiber (HF) FlFFF that uses a piece of porous HF as separation channel [(10 ) and references therein], has shown advantages not only because the channel is of reduced volume, but also because it is simple to construct and inexpensive, making it potentially disposable (11 ) . Disposable FlFFF channels should be particularly advantageous in clinical analysis, for which sample carryover must be strictly avoided.
Since its early development stage, FlFFF has been used to fractionate lipoproteins (12 ) . FlFFF was used to characterize LDL particles of patients with CAD (13 ), and HF FlFFF of LDL particles from CAD patients and from healthy donors was recently reported (14 ) . However, no independent, uncorrelated measurements of the fractionated LDL size were used to fully characterize serum lipoproteins in size and shape.
Multiangle light scattering (MALS) allows for the absolute determination of molar mass (M w ) and particle size over a broad range (15 ) . If MALS is not coupled to a size-based separation device, however, it gives only mean values. Online FlFFF-MALS makes it possible to size-sort macromolecules and particles and to online characterize the narrowly dispersed fractions without using standards. Thus, distribution of the absolute M w values can be obtained even for broadly dispersed samples if the concentration and specific refractive index increment (dn/dc) are also measured or known. The root mean square gyration radius (R g ) can be calculated from the angular dependence of the MALS signals alone, without information on dn/dc (15 ) .
This study was the 1st to investigate the feasibility of FlFFF-MALS as a method for size and shape characterization of lipoproteins from whole human serum samples. Because MALS was applied to HF FlFFF for the accurate estimation of M w and size values of protein aggregates (16 ), we compared the performance of the method when used with either commercial FIFFF or prototype HF FlFFF instruments. The method will require further validation and verification to be applied on a routine scale.
Human blood serum samples were obtained from healthy donors who gave informed consent. Samples were stored at Ϫ20°C until analysis. In some experiments, sera were stained before the analysis with Sudan Black B (SBB; Fluka), a dye for lipid components, which generates a specific absorption maximum at 600 nm. For these experiments, a volume of 2 L SBB solution (1% wt/vol in ethanol) was added to 100 L serum and 400 L phosphate buffer (7.5 mmol/L KH 2 PO 4 , 7.5 mmol/L Na 2 HPO 4 ϫ 2 H 2 O, pH ϭ 7.2).
The commercial FlFFF system was the model Eclipse 2 (Wyatt Technology Europe). The channel had a trapezoidal shape, with 350-m thickness and 175-mm length, and with breath decreasing from 18 mm (inlet end) to 3 mm (outlet end). The accumulation wall was a 30 000-Da cutoff regenerated cellulose membrane.
The prototype HF FlFFF channel was built up as described elsewhere (11, 17 ) . A piece of polyacrylonitrile HF membrane was sheathed by 2 pieces of one-eighth inch outer diameter Teflon tube. A T connection was positioned between the 2 tubes to make the radial flow outlet. Hand-tight male fittings were positioned at the channel inlet and outlets. The HF membrane had a 30 000 M r cutoff, nominal inner radius of 0.40 mm, and a length of 240 mm (dried conditions).
The mobile phase was phosphate buffer (7.5 mmol/L KH 2 PO 4 , 7.5 mmol/L Na 2 HPO 4 ϫ 2 H 2 O, pH ϭ 7.2) degassed with a 1100 Series vacuum degasser (Agilent Technologies) and delivered by a 1100 HPLC iso-pump (Agilent). The injected sample volume was 10 L (with the commercial FlFFF channel) or 4 L (with the prototype HF FlFFF channel). With either the commercial FlFFF or the prototype HF FlFFF channel, flow rates and patterns were controlled using the Eclipse 2 separation system. The FlFFF and HF FlFFF operation conditions are reported in the Fig. 1 legend.
Fractionated components were online detected as a function of retention time, and a serum profile (fractogram) was recorded. Detection was performed by an HP1100 UV and visible diode array detector (Agilent), operated at 280 and 600 nm wavelengths, a refractive index detector model Optilab rEX (Wyatt Technology) , and a MALS detector model DAWN HELEOS (Wyatt Technology). ASTRA software version 5.3.1 (Wyatt Technology) was used to handle signals from the detectors and to compute the R g values.
A serum profile obtained using the commercial FlFFF channel is shown in Fig. 1A . The concentrations were known for TC (5.05 mmol/L, 195 mg/dL) and TG (5.36 mmol/L, 473 mg/dL). Total analysis time was approximately 1 h. The scattering intensity signal shows bands not only for the main lipoprotein classes (HDL, LDL, VLDL) but also for the most abundant serum proteins (albumin, IgG). Assignment of the lipoprotein bands was then necessary. The MALS trace was compared with the UV trace at 280 nm, in which the lipoprotein bands were hardly detectable owing to their low concentration. Using SBB-stained samples, we then compared the MALS trace with the UV trace at 600 nm, in which the stained lipoproteins were the only detected species. One band ascribed to IgG (band 2) and 3 bands ascribed to the HDL coretained with albumin (band 1), to LDL (band 3), and to VLDL (band 4) were found. According to FlFFF theory, lipoproteins are eluted at retention times that increase with increasing R h values (12 ) . The R h values we obtained (top x axis) were in reasonable agreement with those previously obtained by other method: 2-7 nm for HDL,calculated the height values for model disk-like LDL particles. By applying a hydrodynamic model for disklike particles (19 ), we obtained for LDL a predicted range for R g /R h of 0.787-0.830. The experimental LDL R g /R h values we obtained for a set of serum samples were in the range 0.38 -1.38. These values are higher than those expected for either a homogeneous sphere (R g /R h ϭ 0.774) or for the above disk-like model (R g /R h ϭ 0.787-0.830). However, LDL particles are core shell with nonhomogeneous density (20 ) , with the shell denser than the core. Because R g /R h increases with increasing contribution of the shell to the LDL mass distribution, our results are compliant with a core-shell, discoidal conformation. Finally, from band intensities the relative abundance of the different lipoprotein classes can be determined: high intensity of band 4, for instance, reflects the known correlation existing between TG concentration and VLDL content.
Compared with the profile in Fig. 1A , the profile obtained with the same serum sample by use of the prototype HF FlFFF channel (Fig. 1B) shows a lower signal-to-noise ratio, likely because of the lower sample load. The lipoprotein classes (bands 1, 3, 4) , however, are fractionated with comparable resolution, and the calculated R h values are also comparable. Because of the different flow conditions used in HF FlFFF, the VLDL band (band 4) is broader, but, as also plotted in Fig. 1B , the increase in R g values across the VLDL fraction indicates that band broadening is not due to a separation efficiency lower than in commercial FlFFF but to the high size-based selectivity of HF FlFFF. One of the fundamental goals in biology is to understand the complex spatiotemporal interplay of biomolecules from the cellular to the integrative level. To study these interactions, researchers commonly use fluorescent labeling for both in vivo cellular imaging and in vitro assay detection (1, 2 ) . In this context, one of the fastest developing and most exciting interfaces of nanotechnology is the use of inorganic quantum dots or fluorescent nanoparticles in cell biology. The unique optical properties of inorganic particles make them appealing as in vivo and in vitro fluorophores in a variety of biological investigations.
In addition, the ability to make such nanoparticles and then target these particles to specific biomolecules has led to promising applications in cellular labeling, deep-tissue imaging, and assay labeling, and also as efficient fluorescence resonance energy transfer donors.
Conventionally used fluorescent labels, such as organic dyes in cell biology, are prone to problems such as broad spectral features, short lifetime, photobleaching, and potential toxicity to the cells. Inorganic fluorescents, especially europium (Eu) and terbium (Tb) in the lanthanide group, have several unique optical and electronic properties, such as size-and composition-tunable emission from visible to infrared wavelengths, large absorption coefficients across a wide spectral range, symmetric emission spectrum, a large Stokes shift, simultaneous excitation of multiple fluorescent colors, very high levels of brightness, and photostability (3) (4) (5) . Furthermore, analysis by cell proliferation and apoptosis assay (dUTP nick-end labeling) showed that lanthanide phosphate (LnPO 4 ⅐ H 2 O, where Ln ϭ Eu) and Tb nanorods synthesized by microwave (MW) were nontoxic to endothelial cells (5 ) .
In speed of chemical reactions is enhanced with minimal energy output and thus the heating energy is very focused; in contrast, the use of a heating plate wastes more energy; (b) 2.45-GHz radiation is not harmful; and (c) the solvents used, such as water and ethanol, efficiently absorb MW radiation and are also considered environmentally friendly. The as-synthesized EuPO 4 ⅐ H 2 O products consisted of nanorods (6 to 8 nm in diameter and 100 to 300 nm long), and TbPO 4 ⅐ H 2 O products were a mixture of 2 rod types in micrometer sizes (small rods 0.5 to 1.5 m long and 6 to 8 nm wide, and bigger rods 1.1 to 2.2 m long and 80 to 130 nm wide) (5 ) .
We prepared the LnPO 4 ⅐ H 2 O nanorod suspension in sterile Tris-EDTA buffer and used only freshly prepared suspension for all cell culture experiments. HUVEC and 786-O cells were cultured at 10 5 cells/2 mL in 6-well plates for 20 h at 37°C and 5% CO 2 in endothelial cell basal medium and DMEM, respectively. For detection of cellular localization of LnPO 4 ⅐ H 2 O nanorods, after 20 h of incubation with these nanorods, the cells were washed with PBS [KH 2 PO 4 (0.144 g/L; 1.06 mM), NaCl (9 g/L; 153.8 mM), Na 2 HPO 4 (anhydrous) (0.795 g/L; 5.6 mM), pH 7.4], trypsinized, neutralized, and washed by centrifugation. The cells were then resuspended in fixative liquid and analyzed with a TEM according to the accepted protocol (7, 8) . For investigation of fluorescence images (by use of confocal microscopy), cells were plated on glass coverslips and grown to 90% confluence, after which they were incubated with LnPO 4 ⅐ H 2 O nanorods at a concentration of 50 -100 mg/L. After 20 h of incubation, the coverslips were rinsed extensively with PBS; cells were fixed with freshly prepared 4% paraformaldehyde in PBS for 15 min at room temperature and then rehydrated with PBS. When all the cells were fixed, the coverslips were mounted onto glass slides with Fluor Save mounting media and examined with confocal microscopy. The minimum concentration of the nanorods used for internalization in the RCC/HUVEC and visualization by transmission electron microscopy/confocal microscopy was 10 mg/L (data not shown).
The internalization of LnPO 4 ⅐ H 2 O nanorods inside the cells was visualized with a TEM according to previously published procedures (7, 8) . cell. The exact nature of the cytoplasmic vesicles is currently under investigation as part of a future project, but it appears that nanorods internalize in double-membrane layered early endosomelike compartments away from the nucleus or late endosomelike structures close to the nucleus. Two-dimensional, confocal fluorescence microscopy images were collected through the use of an LSM 510 confocal laser scan microscope (Carl Zeiss) with a C-Apochromat 63 X/NA 1.2 water-immersion lens in conjunction with an argon ion laser (364 and 488 nm excitations were used for Eu and Tb, respectively). The red and green fluorescence emissions were collected through a 601-and 505-nm long-pass filter for EuPO 4 ⅐ H 2 O and TbPO 4 ⅐ H 2 O nanorods, respectively, and are shown in Fig. 1 , A and C. A red fluorescence (Fig. 1A) of EuPO 4 ⅐ H 2 O nanorods and its corresponding phase image (Fig. 1B) are observed in Fig. 1, A and B . Similarly, a green fluorescence (Fig. 1C) of TbPO 4 ⅐ H 2 O nanorods and its corresponding phase image (Fig. 1D) are shown in Fig. 1 , C and D. Furthermore, the fluorescence ( Fig. 1, E , G, and I) and corresponding phase image (Fig. 1,  F (Fig. 1G) and green ( Fig. 1I ) fluorescence between the untreated control cells (Fig. 1E ) and the nanorod-treated cells (Fig. 1, G and I) . Similar results were obtained for HUVECs after treatment with LnPO 4 ⅐ H 2 O nanorods (see Fig. SI-2 in the online Data Supplement). These results demonstrate the internalization of LnPO 4 ⅐ H 2 O nanorods inside 786-O and HUVECs. One of the most important results was that under the new settings of the confocal microscope, we were able to clearly distinguish the great difference in red and green fluorescence intensities between untreated control cells and nanorodtreated cells, whereas in our earlier study, autofluorescence was present in control untreated cells (5 ) .
Taken together, these results indicate that these fluorescent nanorods can internalize in cells, which in turn can be visualized by microscopy. Therefore, these nanorods offer useful and alternative inorganic fluorescent probes for targeting various molecules in living cells.
Furthermore, we also report the use of inorganic fluorescent EuPO 4 WNV, a member of the Flaviviridae family, belongs to the Japanese encephalitis serocomplex that includes Japanese encephalitis and St. Louis encephalitis viruses (3 ). WNV is transmitted to humans by mosquitoes. The transmission cycle involves mosquitoes and birds. In rare instances, the virus may be transmitted from human to human through organ donation or blood transfusion or from pregnant mother to fetus (4 -6 ) . WNV infections in a pediatric population have also been reported (7 ). Many patients remain asymptomatic or have only mild symptoms. Others report having fatigue, rash, fever, headache, and muscle weakness and may require hospitalization (8 ) . The more severe form of the disease is meningoencephalitis manifested by typical signs of central nervous system infection and, in a minority of cases, development of a flaccid paralysis (9 ) .
Symptomatic patients will demonstrate an early antibody response of the IgM type during the 1st 4 days of illness, and nearly all patients will have detectable IgM antibodies by 7 to 8 days after the onset of illness (10 ) . WNV-specific serum IgG is detectable by 3 weeks postinfection (11 ) . The virus itself is usually no longer detectable by the time WNV-specific serum IgM appears, although both IgM and IgG may persist for more than a year (12 ) . Laboratory-based ELISAs designed to detect WNV-specific IgM are now accepted as a sensitive early marker for WNV infection (13) (14) (15) . However, current ELISA assays (e.g., Focus Technologies West Nile Virus IgM Capture ELISA, PanBio) are multistep procedures that require 5-6 h to perform, instrumentation to read the tests, and subsequent calculations to interpret the test results. We describe the development of a novel and a rapid WNV IgM strip test (RapidWN™) that requires minimum sample preparation and produces results visibly in 15 min. We show that such results are substantially equivalent to currently used ELISA devices (e.g., CDC WNV IgM ELISA, Focus Technologies West Nile Virus IgM Capture ELISA).
Both the ELISA and the strip format assay use the same principle and the same WNV antigen (suckling mouse brain WNV protein E or recombinantly produced WNV protein E fraction) and flavivirus-specific monoclonal antibody 6B6C-1. The RapidWN uses solid-phase immunochromatographic strip technology to qualitatively detect the presence of WNV IgM antibodies in human serum or plasma. The test uses a fragment of recombinant WNV envelop protein (antigen) that was expressed in Escherichia coli, purified, and characterized. Antibody 6B6C-1, provided by the CDC as a hybridoma cell line, was cultured and purified. Goat-antihuman IgM (Jackson IRL) was biotinylated (biot-␣h-IgM) and 6B6C-1 antibody was conjugated onto colloidal gold particles (detector). All 3 reagents were then dispensed onto the polyester pad and lyophilized. Streptavidin was recombinantly produced and immobilized onto a nitrocellulose (Sartorius) membrane strip at the test-band site. Rabbit antimouse IgG-Fc was immobilized at the control-band site.
When the specimen is dispensed into the sample well, it passes through the membrane, which contains antigen, detector, and biot-␣h-IgM antibodies. The WNV IgM in the patient sample then forms a tertiary detector/antigen/IgM complex. The formed complex then migrates through the reaction strip and is captured at the test area. Excess, unreacted detector flows through the strip and is captured in the control area. The reactant concentrations are adjusted and optimized by analysis of calibrators, made from pooled WNV-positive sera, so that the test should produce a positive signal at WNV IgM Index value Ն1.1 of an commercially available Focus Technologies West Nile Virus IgM Capture ELISA device (comparator device) and negative results below that number. Examples of positive, negative, and invalid test results are shown in Fig. 1 .
Visible pinkish-purple horizontal bands appear in the test area if the concentration of the WNV IgM antibodies in the human serum sample is above the cutoff concentration in relation to the comparator device. A pinkishpurple band in the control area indicates that the test is working properly, and such a band must always appear, irrespective of the WNV IgM concentration, for the test to be considered valid.
RapidWN test precision studies were performed using a reproducibility panel made of different clinical serum specimens at 3 study sites during a 3-day period. Each day a new lot was used and a different operator was used. This 15-member reproducibility panel (blinded) consisted of 6 clinical specimens with a mean index value 25% above the cutoff, 6 clinical specimens with a mean index value 15% below the cutoff, and 3 clinical specimens with a mean index value 6 times the cutoff of the comparator device. All sites and operators produced the expected result for all panel members on every day of testing. Near-cutoff positive and negative samples also produced expected results when tested by 3 operators on the same lot for 10 consecutive days.
No significant interferences were found with common serum analytes such as human serum albumin, bilirubin, hemoglobin, or triglycerides at 2 to 3 times the normal expected values. No cross-reactivity with Japanese, Saint Louis, California, or Eastern equine encephalitis viruses was observed, but some cross-reactivity (10%) with Dengue virus was noted.
Reactivity with autoantibodies, such as antinuclear antibodies and rheumatoid factor, is common to all immunoassays (16 ) , and the RapidWN test is not an exception. Care has been taken to block such activities at heterophile antibody titers commonly encountered in a population, but rare samples with higher titers may affect the test.
Clinical specificity of the RapidWN test was assessed on prospective specimens (n ϭ 346) after institutional review board approval at 3 study sites from endemic regions of the US and Canada. Samples were from presumably healthy individuals (n ϭ 67) or patients with non-WNV ailments (n ϭ 279), including 61 febrile pa-tients. The study group was 47% men and 53% women. There was 99% agreement between methods, with few incidences of heterophile antibody interferences ( Table 1) .
Studies of diagnostic accuracy were conducted following institutional review board approval at 3 sites on randomized blinded retrospective samples from patients with clinical symptomology consistent with WNV infection. Results presented in Table 1 showed that the RapidWN test produced 100% agreement of serological sensitivity for acute, CDC WNV IgM and IgG ELISA-positive and plaque neutralization reduction test (PRNT)-confirmed samples. There was Ͼ97% agreement with other positive samples (CDC WNV IgM and IgG ELISA positive and PRNT confirmed) and 96% agreement with the CDC WNV ELISAnegative specimens. Similar results were obtained when comparison was made with the comparator device. The RapidWN test produced 98% agreement with the WNVnegative and 95% agreement with WNV-positive specimens. The apparent decrease in serological sensitivity is partially due to the fact that ELISA-based devices may produce equivocal results for some samples (index values between 0.9 and 1.09 of the comparator device), whereas a strip test may show positive/negative results within the 10% limit of the cutoff values.
The RapidWN test can also be used on plasma samples. The device produced similar results on 63 cohort plasma and serum samples when tested concomitantly. This test can also be equally performed on cerebrospinal fluid samples (unpublished results). The efficacy of ELISA-based or microsphere immunoassays for detecting WNV antibodies has been well documented and provided results confirmed by PRNT (12-14, 17, 18 ) . The RapidWN strip test described here also showed comparable results with the ELISA-based IgM tests and with the PRNT. However, the advantages of the strip test over currently marketed ELISA-based tests include rapid result generation (15 min), ease of use, room temperature stability, and visually readable results. In addition, the strip test can be used for a single sample or multiple samples. Hence, the cost:benefit ratio of a rapid strip test may be better than that of traditional ELISA devices because of decreased labor time, equipment costs, and transport times for samples and test results. Other commonly used immunochromatographic strip tests that generate results visibly have been clinically validated for patients suspected of myocardial ischemia (19 ) . The data presented here show that the RapidWN strip test can be effectively used as a rapid visible test for patients suspected of WNV infections. molecule; essentially, a sample is scavenged for its ATP content. In the next step of the reaction the AMP nucleotide is transferred to the 5Ј phosphate of the nicked-DNA strand, followed by attack on the AMP-DNA bond by the 3Ј-OH of the nicked DNA to generate an intact phosphodiester backbone. This product then forms a template for a subsequent DNA amplification process, typically PCR. In this coupled process the catalytic activity of the enzyme is amplified by the NAT process, leading to very high signal generation.
A preferred configuration of the LiMA procedure is to immobilize the deadenylated ligase on the surface of a paramagnetic bead. This reagent can then be added to a dilute ATP solution, left to accumulate ATP (in the form of the stable AMP-charged enzyme intermediate), and then concentrated (using a magnet) before detection of ligase activity in the NAT process. This procedure provides additional sensitivity, because it allows much larger sample volumes to be easily measured (Ͼ1 mL). A further advantage of the magnetic bead-based approach is that any DNA-amplification inhibitors present in the specimen can be removed by washing before the NAT process. Further improvements in the ATP assay can be achieved by immobilizing both the ligase and the nicked-DNA substrate on the paramagnetic bead to reduce the reagent additions required in the assay. This process also provides further rate enhancement because of the proximity of enzyme and substrate on the bead.
The reagents for the LiMA procedure were prepared and stored at 4°C before use in the ATP assay. To couple ligase to the solid phase, 500 L Dynal M270 amine paramagnetic beads were washed in standard PBS (120 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L phosphate buffer, pH 7.4) with a magnetic separation device and activated by incubation with 1 g/L suberic acid hydroxyl succinate ester (Sigma Aldrich) in PBS for 30 min at room temperature (22°C) with shaking. Meanwhile, 4000 U of T 4 DNA ligase (New England Biolabs) were deadenylated for 30 min at room temperature in 50 mmol/L HEPES, pH 7.5, 5 mmol/L sodium pyrophosphate, and 10 mmol/L dithiothreitol (DTT) in a volume of 500 L. The activated magnetic beads were then washed twice in PBS and once in 50 mmol/L HEPES, pH 7.5, and the deadenylated ligase was added to the washed beads and incubated for 30 min at room temperature with shaking. The immobilized ligase magnetic beads were washed twice in 50 mmol/L HEPES, pH 7.5, 5 mmol/L sodium pyrophosphate, and 10 mmol/L DTT and incubated in 500 L of this wash solution for 10 min to ensure deadenylation of any remaining active enzyme. Finally the immobilized ligase magnetic beads were washed 5 times with Trisbuffered saline (TBS), 10 mmol/L DTT, 10 mmol/L ethanolamine, and 1 mmol/L MgCl 2 and stored in 500 L of this buffer (ligase buffer) at 4°C before use. Magnetic beads with both ligase and streptavidin immobilized on the surface were prepared according to the method described above, except that 1 mg of streptavidin (Sigma Aldrich) was added to the deadenylated ligase solution before coupling to the beads. After being washed 3 times with TBS containing 10 mmol/L DTT, 10 mmol/L ethanolamine, and 1 mmol/L MgCl 2 , 10 ng of the preformed nicked-DNA substrate (for sequences see below) with a 5Ј biotin moiety was added, incubated for 1 h at 4°C, and washed 3 times with the TBS buffer above. The ligase/ streptavidin/DNA magnetic beads were then stored in ligase buffer at 4°C. The nicked double-stranded DNA substrate was prepared by heating a mixture containing 10 ng of each of the 3 oligomers to 95°C for 5 min and cooling to room temperature. The sequences used were as follows: 5ЈbiotinGCCGATATCGGACAACGGCCGAAC TGGGAAGGCGCACGGAGAGA3Ј, 5ЈCCACGAAGTAC TAGCTGGCCGTTTGTCACCGACGCCTA3Ј, and 5ЈTAG TACTTCGTGGTCTCTCCGTGC3Ј.
In the LiMA procedure for ATP, 25 L of ligase magnetic beads, prepared as described above, were captured magnetically, and the supernatant liquid was removed. The beads were then resuspended in a 20-L reaction volume containing serial dilutions of ATP in 0.6ϫ TBS with 1 mmol/L MgCl 2 and 10 ng of the preformed nicked-DNA substrate. After 15 min at room temperature to allow ligation, 5 L of each reaction was analyzed by PCR under standard conditions (each cycle was 94°C for 10 s, 65°C for 10 s, and 72°C for 10 seconds; 40 cycles were performed) with the following PCR primers: 5ЈGGACAACGGCCGAACTGGGAAGGCG3Ј and 5ЈTAGGC GTCGGTGACAAACGGCCAGC3Ј. The double-stranded DNA intercalator dye SYBR® Green I (Eurogentec) was included in the PCR master mix to detect amplicon generation. The Chromo4 real-time system (MJ Research) was used to measure fluorescence increase in microplate wells. The signal generated in the PCR process was proportional to the amount of ATP present in the sample (Fig. 1, A and B) . The LiMA procedure detection limit for ATP was 0.5 nmol/L (10 fmol) in the sample volume of 20 L used in the assay, calculated using 2.5ϫ SD on 10 replicates of the zero calibrator). The dynamic range was at least 100 000-fold (to Ͼ50 mol/L).
The LiMA process was used to detect bacteria in culture medium. Staphylococcus aureus ATCC no. 25923 was grown in standard nutrient broth culture medium (Merck) until stationary phase was reached. Bacteria in 100 L samples from serial dilutions of this culture were lysed by the addition of 10 L of 0.5 mol/L sodium hydroxide containing 10 mL/L Triton X-100 and heating to 95°C for 3 min After cooling to room temperature, the mixture was neutralized with 10 L of 0.5 mol/L hydrochloric acid. In the subsequent LiMA procedure there were 3 main steps: ligation, washing/elution, and PCR detection. In step 1 the lysed bacterial culture samples containing ATP were mixed and incubated for 15 min with 1 mL of ligase/streptavidin DNA magnetic bead reagent. In step 2 the beads were washed 3 times with TBS, the PCR reagent mix was used to resuspend the beads, the mix was heated to 95°C for 5 min to elute the ligated DNA, and 20 L of the supernatant was transferred to a microplate well.
Step 3 was the PCR process with measurement of increasing fluorescence in the microplate wells over 60 min. The total LiMA procedure time was 85 min. The detection limit ranged from 10 4 to 10 5 S. aureus cells (calculated using 2.5ϫ SD on 10 replicates of the zero calibrator). Although LiMA is still at an early stage of development, the performance of this method with viable bacterial cells is comparable to that of the best luminescence systems available.
The LiMA technology allows quantitative measurement of viable bacteria and other ATP-containing samples such as yeast and eukaryotic cells by use of standard NAT instrumentation and reagents. This procedure brings together both species identification and functional (growth-based) analyses on the same highly developed laboratory platform.
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